Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.51 |
| ▸ | MAOA | P21397 | 4/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2607820 | 0.84 | MAOB (0.40) | MAOBMAOAPTPN1PTGS2ALDH1A1 | |
| SCHEMBL29215168 | 0.81 | MAOB (0.51) | MAOBMAOAPTPN1PTGS2ALDH1A1 | |
| SCHEMBL12622645 | 0.77 | ALDH1A1 (0.52) | MAOBMAOAALDH1A1MAPTCYP3A4 | |
| SCHEMBL23467463 | 0.76 | ALDH1A1 (0.44) | MAOBMAOAPTPN1PTGS2ALDH1A1 | |
| Methylchromone SCHEMBL29387804 | 0.75 | MAOB (0.56) | MAOBMAOAPTPN1PTGS2ALDH1A1 | |
| Methylchromone SCHEMBL25934 | 0.75 | MAOB (0.56) | MAOBMAOAPTPN1PTGS2ALDH1A1 | |
| SCHEMBL11639718 | 0.74 | MAOB (0.51) | MAOBMAOAPTPN1PTGS2ALDH1A1 | |
| SCHEMBL23031958 | 0.74 | MAOB (0.65) | MAOBMAOAPTPN1PTGS2CYP17A1 | |
| Methylchromone SCHEMBL29160528 | 0.73 | MAOB (0.55) | MAOBMAOAPTPN1PTGS2ALDH1A1 | |
| SCHEMBL13543184 | 0.73 | MAOB (0.66) | MAOBMAOAADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339958-A1 | NON-HYDRATED KETONE INHIBITORS OF NAV1.7 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339958-A1 | NON-HYDRATED KETONE INHIBITORS OF NAV1.7 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230065217-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20220009938-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | disclosed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2007032028-A1 | THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065217-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | MAOB 3777/4885MAOA 3860/4885PTPN1 1363/4885 |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | MMP8, MMP26, MMP9 | MAOB 2549/4885MAOA 2198/4885PTPN1 4643/4885 |
| US-20230339958-A1 | NON-HYDRATED KETONE INHIBITORS OF NAV1.7 FOR THE TREATMENT OF PAIN | SCN7A, SCN10A, HCN3 | MAOB 4218/4885MAOA 4489/4885PTPN1 1188/4885 |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | PTPRF, PTPA, PTPRJ | MAOB 202/4885MAOA 658/4885PTPN1 7/4885 |
| US-20220009938-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SCN11A, SCN10A, SCN3A | MAOB 3088/4885MAOA 3546/4885PTPN1 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.